Avastin User Fee Date (correction)
This article was originally published in The Pink Sheet Daily
Executive Summary
Genentech's Avastin (bevacizumab) has a user fee date in June under a priority review for patients with previously treated metastatic colorectal cancer. "The Pink Sheet" DAILY had reported an incorrect user fee date for the new indication in a May 23 1article
You may also be interested in...
Avastin Trial Enrollment To Resume With Heightened Cardiac Monitoring
Roche/Genentech's AVANT study of bevacizumab showed no increase in cardiac adverse events, according to an independent data safety monitoring board.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.